Therefore, the present results suggest that CF, a PPAR agonist that has been widely used in the clinical handling of hyperlipemias, is worth being further scrutinized as a potential low-toxicity and low-cost drug for leukemia therapy. This evidence concerns the gene PPARA and familial hyperlipidemia.